Dr. Jason Zhu is the Executive Director and Chief Executive Officer. Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. 

Ms. Ping Cao, Senior Vice President and Chief Business Development Officer, is in charge of the Business Development Department, responsible for the Company's business cooperation with external partners, including licensing in and out, authorization, partnership alliance, merger and acquisition. Ms. Cao graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.

Mr. James Guo, Senior Vice President, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug, the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Shanghai Labor Medal, Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. Under his leadership, Henlius was awarded 2021 National Worker Pioneer, 2021 Shanghai Worker Pioneer, 2020 Shanghai Model Group and 2019 Shanghai Worker Pioneer.  
In addition, he is the member of the Pharmaceutical Innovation Investment Specialty Committee of China Pharmaceutical Innovation and Research Development Association (PhIRDA), the vice-chairman of Shanghai Biopharmaceutics Industry Association (SBIA) and the member of the 9th council of Shanghai Pharmaceutical Profession Association (SPPA). 

Ms. Jessie Li, Senior Vice President and Chief Human Resource Officer, is responsible for overall HR strategy, organization development, talent strategy. Ms. Jessie Li brings with her over 20 years of HR management experiences, and prior to joining Henlius, she worked in TCCP, Astra Zeneca, De Lage Landen, Kodak Healthgroup/Carestream as HRVP, Executive HR Director, Head of China HR. Ms. Jessie Li holds Bachelor degree from Shandong Finance University in International Finance in 1998, and MBA from Shanghai University of Finance and Economics – Webster University in 2002.

Dr. Frank Ye，Vice President and Chief Quality Officer, is responsible for the overall strategic planning and operational implementation of the Global Quality Operation Department, including Quality Assurance, Quality Control, and Quality Systems management. Dr. Frank Ye holds PhD degree from the UNC in Biostatistics, Master and Bachelor degree from UO. Prior to joining Henlius, Dr. Frank Ye served for several well-known domestic and international companies such as Schering-Plough in the US, GSK in the UK, Amgen in the US, HJB and Transcenta Holding, engaged in drug production and quality management. He has over 20 years of rich experience in biopharmaceutical production, quality management, and factory design and operation.

Mr. Max Mao, Vice President and Chief Financial Officer, is responsible for corporate financial strategy and planning, financial operation management, etc. Max holds his MBA degree of BI Norwegian Business School - Fudan University MBA Program and bachelor’s degree in economics with major in international accounting from Shanghai University of Finance and Economics. Max is a Certified Public Accountant and holds a legal professional qualification in China. Prior to joining Henlius, Mr. Max Mao has more than 20 years of experience in financial related, he joined Fosun Group in March 2019 and successively served as Chief Financial Officer of Health Holdings, Deputy Chief Financial Officer and General Manager of Finance Department of the Great Health Industry Operating Committee, and Co-chief Financial Officer and General Manager of Finance Department of the Health Industry Committee. Before that, he took a role as key financial management positions in companies such as Deloitte, Coca-Cola, Bayer Pharma and UCB.

Ms. Li Jin, Vice President of Regulatory Affairs, is responsible for the global strategic planning and operational management of Regulatory Affairs Department. Ms. Li Jin graduated from Beijing University of Chinese Medicine with a Bachelor’s degree in Traditional Chinese Medicine. She has about 22 years experience in regulatory affairs. Prior to joining Henlius, she held the key position in many different types of companies, including local and multi-national ones, for example Nuance, Mundi Pharma, Merck Serono, Amgen, MSD and China Grand Enterprises, etc. She also had 5 years medicine research experience in pharmaceutical R&D center. Her ability to control different stages of different products is excellent due to previous experienced in various types of companies, including small molecular, biological and medical device products, etc. In addition, she has rich team management skill, especially on team building up and member development. 

Dr. Ely Benaim has executive oversight across the U.S. Clinical Development related matters and has also served as a critical medical leader providing cross-functional support to the R&D and BD of Henlius.

Dr. Benaim received his M.D. from the Universidad Central de Venezuela, and completed his residency training at the University of South Florida. He completed fellowships in the department of Hematology oncology, bone marrow transplantation and Gene Therapy program at St. Jude's Children's Research Hospital. Meanwhile, he worked as Assistant Professor in the department of Pediatrics at University of Tennessee. Later, he transferred into drug development industry and taken CMO or other senior positions at Amgen, Takeda Oncology, Berg, Rexahn Pharmaceuticals, Novocure and others. Prior to joining Henlius, he was Chief Medical Officer for SonALAsense. He brings over twenty-five years in the scientific and medical field, including 17 years in the biopharmaceutical industry.

Mr. Guangri Sun, Deputy General Manager of the Oncology Business Unit, leads Sales Operations Department I with accountability for the sales of the company's oncology portfolio. Prior to joining Henlius, Mr. Sun accumulated over 16 years of pharmaceutical industry experience through progressively senior roles at companies including Zai Lab, AstraZeneca, and Eli Lilly. He possesses extensive expertise in team building, execution of key market strategies, and innovative sales model development, having successfully driven growth for multiple oncology products throughout his career.

Ms. Nancy Wang, Board Secretary and Deputy General Manager of Public Relations, is responsible for the organization of Shareholder General Meeting, Board Meeting and its committee meeting, and Supervisor Meeting as well as the information disclosure. She also takes charge of corporate branding and public relations. Previously, Ms. Wang has successively acted as Supervisor of the Marketing Department, Securities Affairs Representative and Manager of Public Affairs Department, Director of the Office of Board Secretary and Executive Director of Public Relations of the Company. Ms. Wang obtained her Bachelor’s degree in Bio-pharmacy from Nanjing Forestry University in 2010 and a Master’s degree in Biochemistry in 2013 from the same university.